Posted On: 09/20/2016 1:06:20 PM
Post# of 63866
$RGBP dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
10 advanced breast cancer patients
Efficacy endpoints at 6 and 12 months
Establishment of safety will allow for rapid expansion of patient numbers
Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
http://www.regenbiopharmainc.com/product-pipeline.html
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
10 advanced breast cancer patients
Efficacy endpoints at 6 and 12 months
Establishment of safety will allow for rapid expansion of patient numbers
Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
http://www.regenbiopharmainc.com/product-pipeline.html
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
